• +1-646-491-9876
    • +91-20-67278686

    Search

    Insomnia Pipeline Review H1 2017

    Insomnia Pipeline Review H1 2017

    • Report Code ID: RW0001799275
    • Category Pharmaceuticals
    • No. of Pages 99
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Insomnia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H1 2017, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

    Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Insomnia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 10, 4, 9 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

    Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Insomnia - Overview
    Insomnia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Insomnia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Insomnia - Companies Involved in Therapeutics Development
    Actelion Ltd
    Alexza Pharmaceuticals Inc
    Athenex Inc
    Eisai Co Ltd
    Evotec AG
    Grupo Ferrer Internacional SA
    Heptares Therapeutics Ltd
    Intec Pharma ltd
    Intra-Cellular Therapies Inc
    Johnson & Johnson
    Leading BioSciences Inc
    Merck & Co Inc
    Neurim Pharmaceuticals Ltd
    Novartis AG
    Reviva Pharmaceuticals Inc
    Shionogi & Co Ltd
    Taisho Pharmaceutical Co Ltd
    Takeda Pharmaceutical Company Ltd
    Yangtze River Pharmaceutical Group
    Insomnia - Drug Profiles
    (diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CB-2810 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CY-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CY-20 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DORA-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Insomnia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EVT-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HTL-6641 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-48816274 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-7922 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LASSBio-785 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LASSBio-786 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lemborexant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lorediplon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lumateperone tosylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-8133 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MLS-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nebivolol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NEO-1940 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    piromelatine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ramelteon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-117957 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit OX2R for Insomnia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TS-142 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    UCM-765 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    zaleplon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    zaleplon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    zolpidem tartrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    zolpidem tartrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Insomnia - Dormant Projects
    Insomnia - Discontinued Products
    Insomnia - Product Development Milestones
    Featured News & Press Releases
    Mar 02, 2017: Blake Insomnia Therapeutics and Sajo Consulting Introduce Clinical Trial Team Members
    Feb 06, 2017: Ergomed announces positive Phase II top-line results of co-development partner Ferrer's Lorediplon for the treatment of insomnia
    Jan 17, 2017: Blake Insomnia Therapeutics Seeks Financing for Clinical Trials
    Sep 08, 2016: Ergomed Completes Recruitment of Phase IIa Clinical Trial of Lorediplon in Insomnia in Collaboration with co-development Partner Ferrer
    Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
    Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202
    Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients
    Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
    Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe
    Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202
    Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
    Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia
    Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist
    Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
    Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Insomnia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Insomnia - Pipeline by Actelion Ltd, H1 2017
    Insomnia - Pipeline by Alexza Pharmaceuticals Inc, H1 2017
    Insomnia - Pipeline by Athenex Inc, H1 2017
    Insomnia - Pipeline by Eisai Co Ltd, H1 2017
    Insomnia - Pipeline by Evotec AG, H1 2017
    Insomnia - Pipeline by Grupo Ferrer Internacional SA, H1 2017
    Insomnia - Pipeline by Heptares Therapeutics Ltd, H1 2017
    Insomnia - Pipeline by Intec Pharma ltd, H1 2017
    Insomnia - Pipeline by Intra-Cellular Therapies Inc, H1 2017
    Insomnia - Pipeline by Johnson & Johnson, H1 2017
    Insomnia - Pipeline by Leading BioSciences Inc, H1 2017
    Insomnia - Pipeline by Merck & Co Inc, H1 2017
    Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
    Insomnia - Pipeline by Novartis AG, H1 2017
    Insomnia - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
    Insomnia - Pipeline by Shionogi & Co Ltd, H1 2017
    Insomnia - Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017
    Insomnia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Insomnia - Pipeline by Yangtze River Pharmaceutical Group, H1 2017
    Insomnia - Dormant Projects, H1 2017
    Insomnia - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Insomnia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Insomnia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Actelion Ltd
    Alexza Pharmaceuticals Inc
    Athenex Inc
    Eisai Co Ltd
    Evotec AG
    Grupo Ferrer Internacional SA
    Heptares Therapeutics Ltd
    Intec Pharma ltd
    Intra-Cellular Therapies Inc
    Johnson & Johnson
    Leading BioSciences Inc
    Merck & Co Inc
    Neurim Pharmaceuticals Ltd
    Novartis AG
    Reviva Pharmaceuticals Inc
    Shionogi & Co Ltd
    Taisho Pharmaceutical Co Ltd
    Takeda Pharmaceutical Company Ltd
    Yangtze River Pharmaceutical Group

    Request for Sample

    Report Url http://www.reportsweb.com//insomnia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//insomnia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//insomnia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments